PGC-1α research offers new hope for weight loss by boosting metabolic efficiency and providing accessible management ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

The Biden administration is expected to release the next batch of drugs that will be subject to Medicare price negotiations — ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

After a turbulent year, things should calm for payers with the advent of a business-friendly Trump administration — though challenges will persist. Here are experts’ biggest predictions for 2025.

Both Novo Nordisk and Eli Lilly are studying their weight loss drugs to treat fatty liver disease, chronic kidney disease, ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...